ArticleHaematologica2020
Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay.
Article in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study.Blood advances · 2023Trial
- Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma.Acta neuropathologica communications · 2020Trial
- Bridging the Diagnostic Gap in Hereditary Cancers with Simple, Cost-Effective, High-Throughput RNA Splicing Analysis.The Journal of molecular diagnostics : JMD · 2025Article
- Distribution reappraisal of peripheral T- and NK-cell lymphoma entities through the French Lymphopath network database.HemaSphere · 2025Article
- Molecular Insights into the Diagnosis of Anaplastic Large Cell Lymphoma: Beyond Morphology and Immunophenotype.International journal of molecular sciences · 2025Review
- A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas.Blood · 2024Review
- Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes.Cell reports. Medicine · 2024Article
- Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders.Current hematologic malignancy reports · 2023Review
- Article
- Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: A case report.Clinical case reports · 2023Article
- Disequilibrium betweenCancers · 2023Article
- How molecular advances may improve the diagnosis and management of PTCL patients.Frontiers in oncology · 2023Review
- A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability.EMBO molecular medicine · 2022Article
- The EHA Research Roadmap: Malignant Lymphoid Diseases.HemaSphere · 2022Article
- Critical Role of Flow Cytometric Immunophenotyping in the Diagnosis, Subtyping, and Staging of T-Cell/NK-Cell Non-Hodgkin's Lymphoma in Real-World Practice: A Study of 232 Cases From a Tertiary Cancer Center in India.Frontiers in oncology · 2022Article
- Neoplasms of follicular helper T-cells: an insight into the pathobiology.American journal of blood research · 2022Review
- Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification.Journal of clinical and experimental hematopathology : JCEH · 2022Review
- Peripheral T-cell lymphoma: molecular profiling recognizes subclasses and identifies prognostic markers.Blood advances · 2021Article
- Review
- Controversies in the Treatment of Peripheral T-cell Lymphoma.HemaSphere · 2020Review
Corrections and comments
- Commented on by
Authors and funding
26 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral T-cell lymphoma comprises a heterogeneous group of mature non-Hodgkin lymphomas. Their diagnosis is challenging, with up to 30% of cases remaining unclassifiable and referred to as "not otherwise specified". We developed a reverse transcriptase-multiplex ligation-dependent probe amplification gene expression profiling assay to differentiate the main T-cell lymphoma entities and to study the heterogeneity of the "not specified" category. The test evaluates the expression of 20 genes, including 17 markers relevant to T-cell immunology and lymphoma biopathology, one Epstein-Barr virus-related transcript, and variants of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.